Literature DB >> 22984219

Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer.

Zoe Wainer1, Marissa G Daniels, Jason Callahan, David Binns, Rodney J Hicks, Phillip Antippa, Prudence A Russell, Naveed Z Alam, Matthew Conron, Benjamin Solomon, Gavin M Wright.   

Abstract

UNLABELLED: The identification of robust prognostic factors for patients with early-stage non-small cell lung cancer (NSCLC) is clinically important. The International Association for the Study of Lung Cancer has identified both sex and the maximum standardized uptake value (SUVmax) of (18)F-FDG in the primary tumor as measured by PET as potential prognostic variables. We examined the prognostic value of SUVmax in a surgical cohort of patients with NSCLC and disaggregated the findings by sex.
METHODS: Patients who had undergone a preoperative PET/CT scan and surgical resection with curative intent from 2001 to 2009 were identified from a prospective database. An SUVmax cutoff was calculated using receiver-operating-characteristic curves. Overall survival was correlated with SUVmax for the whole cohort and disaggregated by sex.
RESULTS: Inclusion criteria were met by 189 patients: 127 (67%) men and 62 (33%) women. Five-year survival was 54.6% for the whole cohort, 47.7% for men, and 68.2% for women. SUVmax correlated negatively with survival in a univariate analysis for the whole cohort (hazard ratio [HR], 2.51; 95% confidence interval [CI], 1.54-4.09; P < 0.001) and men (HR, 3.42; 95% CI, 1.94-6.05; P < 0.001) but not for women (HR, 1.61; 95% CI, 0.43-3.12; P = 0.77), using 8 as a cutoff. In multivariate analysis, SUVmax correlated with overall survival for the whole cohort (HR, 1.70; 95% CI, 1.05-2.99; P = 0.05) and men (HR, 2.40; 95% CI, 1.32-4.37; P = 0.004) but not for women (HR, 0.80; 95% CI, 0.15-4.47; P = 0.80).
CONCLUSION: SUVmax independently predicted overall survival for men but not for women in this surgical cohort. Our results suggest that SUVmax is an independent prognostic variable in men with surgically treated early NSCLC.

Entities:  

Mesh:

Year:  2012        PMID: 22984219     DOI: 10.2967/jnumed.112.105197

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.

Authors:  Carlos Caicedo; Maria Jose Garcia-Velloso; Maria Dolores Lozano; Tania Labiano; Carmen Vigil Diaz; Jose Maria Lopez-Picazo; Alfonso Gurpide; Javier J Zulueta; Javier Zulueta; Jose Angel Richter Echevarria; Jose Luis Perez Gracia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

2.  Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.

Authors:  Samira M Sadowski; Allison B Weisbrod; Ryan Ellis; Dhaval Patel; Meghna Alimchandani; Martha Quezado; Corina Millo; David J Venzon; Naris Nilubol; W Marston Linehan; Electron Kebebew
Journal:  J Am Coll Surg       Date:  2014-01-18       Impact factor: 6.113

3.  Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer.

Authors:  Chao Tu; Yingqi Pi; Shan Xing; Yang Ling
Journal:  PLoS One       Date:  2020-10-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.